| __timestamp | Novartis AG | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 14993000000 | 5496000 |
| Thursday, January 1, 2015 | 14247000000 | 9786000 |
| Friday, January 1, 2016 | 14192000000 | 6792000 |
| Sunday, January 1, 2017 | 14997000000 | 7313000 |
| Monday, January 1, 2018 | 16471000000 | 8382000 |
| Tuesday, January 1, 2019 | 14369000000 | 10803000 |
| Wednesday, January 1, 2020 | 14197000000 | 12944000 |
| Friday, January 1, 2021 | 14886000000 | 21967000 |
| Saturday, January 1, 2022 | 14253000000 | 32810000 |
| Sunday, January 1, 2023 | 12489000000 | 46542000 |
| Monday, January 1, 2024 | 12566000000 |
Unleashing the power of data
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Novartis AG and Xenon Pharmaceuticals Inc. have demonstrated contrasting approaches to SG&A efficiency.
From 2014 to 2023, Novartis AG consistently maintained high SG&A expenses, averaging around $14.5 billion annually. Despite a slight decline in 2023, their expenses reflect a robust operational scale, essential for a global leader.
Conversely, Xenon Pharmaceuticals Inc. showcased a remarkable growth trajectory. Their SG&A expenses surged by over 700% from 2014 to 2023, indicating aggressive expansion and investment in market presence.
This analysis highlights the strategic differences between an established giant and an emerging contender, offering insights into their financial strategies and market positioning.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Novartis AG and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
GSK plc and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.: SG&A Expense Trends
Genmab A/S vs Xenon Pharmaceuticals Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Walgreens Boots Alliance, Inc. or Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or Ligand Pharmaceuticals Incorporated